Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:22 2024-02-21 am EST 5-day change 1st Jan Change
90.04 CHF -0.80% Intraday chart for Novartis AG +2.55% +6.09%
This article is reserved for subscribers
To unlock the article, SUBSCRIBE!
Already a customer? Log In
UK's MHRA revokes authorisation for Novartis' sickle cell drug RE
NOVARTIS : Novartis on course to set new highs Alphavalue
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB... Our Logo
Swiss Market Index Closes in the Green on Healthcare Stocks Boost MT
Novartis Launches Strategic Review of Listed Indian Business MT
Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India CI
EMEA Morning Briefing : Stocks Seen Lower at Start of Week DJ
Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm CI
Dr Reddy'S In Race To Acquire Novartis AG's Stake In Novartis India - CNBC TV-18 RE
News Highlights : Top Company News of the Day - Friday at 7 PM ET DJ
News Highlights : Top Company News of the Day - Friday at 5 PM ET DJ
News Highlights : Top Company News of the Day - Friday at 3 PM ET DJ
News Highlights : Top Company News of the Day - Friday at 1 PM ET DJ
Novartis AG Announces A Strategic Review of India Unit CI
Novartis, Roche's Food Allergies Treatment Xolair Gets FDA Approval DJ
Novartis AG Announces FDA Approves Xolair® as First and Only Medicine for Children and Adults with One or More Food Allergies CI
Moody's Lifts Novartis' Ratings, Outlook on Solid Operating Performance MT
Erasca Enters Two Supply Deals With Novartis for Trametinib MT
Novartis' Midterm Sales Growth Prospects Limited as Patent Expirations Loom, Berenberg Says MT
INDEX-MONITOR: Morphosys and Vitesco to swap places in MDax and SDax in March DP
This time it's for real Our Logo
Abivax appoints new head of quality CF
NOVARTIS AG : Receives a Buy rating from Deutsche Bank ZD
NOVARTIS : UBS remains Buy on the stock CF
NOVARTIS AG : Gets a Neutral rating from JP Morgan ZD
Chart Novartis AG
More charts
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (81.7%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.; - generic drugs (18.3%; Sandoz). Net sales are distributed geographically as follows: Europe (36.5%), the United States (34.9%), Asia/Africa/Australasia (20.9%), Canada and Latin America (7.7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
103.1 USD
Average target price
109.5 USD
Spread / Average Target
+6.21%
Consensus
1st Jan change Capi.
+6.09% 211 B $
+26.77% 680 B $
+19.01% 546 B $
+0.76% 380 B $
+16.62% 323 B $
+12.34% 310 B $
-5.58% 212 B $
-4.70% 200 B $
-4.53% 156 B $
-2.11% 152 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Novartis AG - Swiss Exchange
  4. News Novartis AG
  5. Novartis : Healthy Q3; guidance upgraded ‘again’
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer